481 related articles for article (PubMed ID: 33485453)
1. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lheureux S; Cristea MC; Bruce JP; Garg S; Cabanero M; Mantia-Smaldone G; Olawaiye AB; Ellard SL; Weberpals JI; Wahner Hendrickson AE; Fleming GF; Welch S; Dhani NC; Stockley T; Rath P; Karakasis K; Jones GN; Jenkins S; Rodriguez-Canales J; Tracy M; Tan Q; Bowering V; Udagani S; Wang L; Kunos CA; Chen E; Pugh TJ; Oza AM
Lancet; 2021 Jan; 397(10271):281-292. PubMed ID: 33485453
[TBL] [Abstract][Full Text] [Related]
2. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
4. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
[TBL] [Abstract][Full Text] [Related]
7. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
8. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
11. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
[TBL] [Abstract][Full Text] [Related]
14. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
16. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Madariaga A; Mitchell SA; Pittman T; Wang L; Bowering V; Kavak N; Quintos J; Chang K; Ramsahai J; Karakasis K; Welch SA; Dhani NC; Lheureux S; Oza AM
Gynecol Oncol; 2022 Nov; 167(2):226-233. PubMed ID: 36055813
[TBL] [Abstract][Full Text] [Related]
17. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C
Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694
[TBL] [Abstract][Full Text] [Related]
18. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
20. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
